Also trades as: ALVO (NASDAQ) · $vol 4M
ALVOW NASDAQ
Alvotech
1W: -39.7%
1M: +69.2%
3M: +18.2%
YTD: -62.1%
1Y: -82.1%
3Y: -55.2%
$0.30
-0.00 (-1.50%)
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.7B
52W Range0.2955-1.52
Volume203
Avg Volume3,690
Beta0.19
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOLisa Graver
Employees1,460
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2022-06-16
Websitealvotech.com
9, Rue de Bitbourg
Luxembourg, LU 1273
LU
Luxembourg, LU 1273
LU
354 422 4500
About Alvotech
Alvotech Holdings SA is an Icelandic enterprise that, operating via its subsidiary companies, undertakes the development and fabrication of biosimilar pharmaceuticals destined for international consumption.
Latest News
Comparing Incyte (NASDAQ:INCY) and Alvotech (NASDAQ:ALVO)
Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
Alvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous Presentations
Has Alvotech (NasdaqGM:ALVO) Fallen Below Fair Value After Its Deal?
Why Alvotech (ALVO) Is Up 11.7% After Expanding Biosimilar Deal With Lotus Pharmaceutical
Recent Insider Trades
No insider trades found